---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-020410"
form_type: "8-K"
ticker: null
cik: "0000793171"
company_name: "Vitro Biopharma, Inc."
filed_at: "2024-05-17T23:59:59+00:00"
generated_at: "2026-06-01T17:50:28.510957+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Vitro BioPharma issues $375K convertible notes at 20% OID and warrants in private placement

## Summary
- Aggregate principal $375,000; purchase price $300,000 (20% original issue discount); interest 20% per annum.
- Notes mature May 16, 2024, extendable to Aug 16, 2024; secured by all company assets.
- Warrants exercisable for 5 years; conversion/exercise terms tied to Liquidity Event or $95M fully-diluted valuation.
- Issued pursuant to prior securities purchase agreement (Nov 16, 2023); exempt under Section 4(a)(2) of Securities Act.

## SEC filing metadata
- accession: 0001493152-24-020410
- form_type: 8-K
- cik: 0000793171
- company_name: Vitro Biopharma, Inc.
- filed_at: 2024-05-17T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/793171/000149315224020410/0001493152-24-020410-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/793171/000149315224020410/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-020410
- JSON: https://secwatch.observer/filing/0001493152-24-020410.json
- Plain text: https://secwatch.observer/filing/0001493152-24-020410.txt

## Key facts
- Debt Financings
  Vitro Biopharma, Inc. incurred convertible notes of $375,000 aggregate principal amount, issued at $300,000 with 20% original issue discount with accredited investors at 20% per annum, accruing from earlier of maturity date or event of default, due f maturing May 16, 2024, extendable to August 16, 2024; or earlier upon a Liquidity Event.
  - Instrument: convertible notes
  - Principal: $375,000 aggregate principal amount, issued at $300,000 with 20% original issue discount
  - Counterparty: accredited investors
  - Rate: 20% per annum, accruing from earlier of maturity date or event of default, due f
  - Maturity: May 16, 2024, extendable to August 16, 2024; or earlier upon a Liquidity Event
  - Event: incurrence
  source text: On May 13, 2024, Vitro BioPharma, Inc. (the “Company”) issued and sold to accredited investors, in a private placement, (i) senior secured convertible notes (the “Notes”) in the aggregate principal amount of $375,000, for an aggregate purchase price of $300,000 (reflecting a 20% original issue discount), and warrants to purchase shares of common stock of the Company (the “Warrants”), pursuant to a previously disclosed securities purchase agreement, dated November 16, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/793171/000149315224020410/0001493152-24-020410-index.htm
- Material Agreements
  Vitro Biopharma, Inc. entered into senior secured convertible notes with accredited investors valued at aggregate principal amount of $375,000 (effective 2024-05-13).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: accredited investors
  - Value: aggregate principal amount of $375,000
  - Effective: 2024-05-13
  source text: On May 13, 2024, Vitro BioPharma, Inc. (the “Company”) issued and sold to accredited investors, in a private placement, (i) senior secured convertible notes (the “Notes”) in the aggregate principal amount of $375,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/793171/000149315224020410/0001493152-24-020410-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.